Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) EPS (Basic) (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed EPS (Basic) for 6 consecutive years, with -$0.31 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Basic) rose 26.19% to -$0.31 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.61, a 31.78% increase, with the full-year FY2025 number at -$1.61, up 31.78% from a year prior.
  • EPS (Basic) was -$0.31 for Q4 2025 at Relay Therapeutics, up from -$0.43 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.31 in Q4 2025 to a low of -$2.1 in Q2 2021.
  • A 5-year average of -$0.66 and a median of -$0.62 in 2024 define the central range for EPS (Basic).
  • Biggest YoY gain for EPS (Basic) was 92.15% in 2021; the steepest drop was 130.99% in 2021.
  • Relay Therapeutics' EPS (Basic) stood at -$0.62 in 2021, then increased by 11.29% to -$0.55 in 2022, then decreased by 21.82% to -$0.67 in 2023, then soared by 37.31% to -$0.42 in 2024, then increased by 26.19% to -$0.31 in 2025.
  • Per Business Quant, the three most recent readings for RLAY's EPS (Basic) are -$0.31 (Q4 2025), -$0.43 (Q3 2025), and -$0.41 (Q2 2025).